Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
arcticnovartis
Fri, 02/28/2025 – 15:04
Read more about Novartis data presentations a…
Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G)
arcticnovartis
Fri, 02/28/2025 – 13:49
Read more about Novartis oral Fabhalta® (iptacopan) receives positive CHMP op…
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
arcticnovartis
Tue, 02/11/2025 – 07:19
Read more about Novartis bolsters late-stage cardiovascular pipeline with agreeme…
Novartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und erreicht 2024 wichtige Meilensteine bei Innovationen
arcticnovartis
Fri, 01/31/2025 – 07:03
Read more about Novartis setzt die starke Umsatzdynamik mit Margenerhöhungen fort und…
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024
arcticnovartis
Fri, 01/31/2025 – 07:03
Read more about Novartis continues strong momentum of sales growth with margin expansion, re…
Novartis Entresto® US patent upheld by US Court of Appeals
arcticnovartis
Mon, 01/13/2025 – 07:19
Read more about Novartis Entresto® US patent upheld by US Court of Appeals
Basel, January 13, 2025 – Novartis is pleased with the dec…
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
arcticnovartis
Mon, 12/30/2024 – 06:49
Read more about Novartis intrathecal onasemnogene abeparvovec Phase III study meets p…
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
arcticnovartis
Tue, 12/10/2024 – 15:04
Read more about Longer-term Novartis Kisqali® NATALEE data show…
Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML
arcticnovartis
Sun, 12/08/2024 – 18:34
Read more about Longer-term data for Novartis Scemblix® re…
New Phase IIIB data shows Novartis Fabhalta® improved hemoglobin levels in adult patients with paroxysmal nocturnal hemoglobinuria who switched from anti-C5 therapy
arcticnovartis
Fri, 12/06/2024 – 07:19
Read more about New Phase IIIB data shows …